Abstract
Protein glycosylation often changes during cancer development, resulting in the expression of cancer-associated carbohydrate antigens. In particular mucins such as MUC1 are subject to these changes. We previously identified an immunodominant Tn-MUC1 (GalNAc-α-MUC1) cancer-specific epitope not covered by immunological tolerance in MUC1 humanized mice and man. The objective of this study was to determine if mouse antibodies to this Tn-MUC1 epitope induce antibody-dependent cellular cytotoxicity (ADCC) pivotal for their potential use in cancer immunotherapy. Binding affinity of mAb 5E5 directed to Tn-MUC1 was investigated using BiaCore. The availability of Tn-MUC1 on the surface of breast cancer cells was evaluated by immunohistochemistry, confocal microscopy, and flow cytometry, followed by in vitro assessment of antibody-dependent cellular cytotoxicity by mAb 5E5. Biacore analysis demonstrated high affinity binding (KD = 1.7 nM) of mAb 5E5 to its target, Tn-MUC1. Immunolabelling with mAb 5E5 revealed surface expression of the Tn-MUC1 epitope in breast cancer tissue and cell lines, and mAb 5E5 induced ADCC in two human breast cancer cell lines, MCF7 and T47D. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity suggesting that antibodies targeting glycopeptide epitopes on mucins are strong candidates for cancer-specific immunotherapies.
Similar content being viewed by others
Abbreviations
- ADCC:
-
Antibody-dependent cellular cytotoxicity
- mAb:
-
Monoclonal antibody
- VNTR:
-
Variable number tandem repeats
- GalNAc:
-
N-acetylgalactosamine
- NeuAc:
-
N-acetylneuraminic acid
- CDC:
-
Complement-dependent cytotoxicity
- MAC:
-
Membrane attack complex
- Gal:
-
Galactose
- PBMC:
-
peripheral blood mononuclear cells
- NK:
-
Natural killer
- FcγR:
-
Fc-γ-receptors
References
Singh, P.K., Hollingsworth, M.A.: Cell surface-associated mucins in signal transduction. Trends Cell Biol. 16(9), 467–476 (2006)
Taylor-Papadimitriou, J., Burchell, J.M., Plunkett, T., Graham, R., Correa, I., Miles, D., Smith, M.: MUC1 and the immunobiology of cancer. J. Mammary Gland Biol. Neoplasia 7(2), 209–221 (2002)
Sorensen, A.L., Reis, C.A., Tarp, M.A., Mandel, U., Ramachandran, K., Sankaranarayanan, V., Schwientek, T., Graham, R., Taylor-Papadimitriou, J., Hollingsworth, M.A., et al.: Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16(2), 96–107 (2006)
Lloyd, K.O., Burchell, J., Kudryashov, V., Yin, B.W., Taylor-Papadimitriou, J.: Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem. 271(52), 33325–33334 (1996)
Tarp, M.A., Clausen, H.: Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim. Biophys. Acta 1780(3), 546–563 (2008)
Hakomori, S., Yamamura, S., Handa, A.K.: Signal transduction through glyco(sphingo)lipids. Introduction and recent studies on glyco(sphingo)lipid-enriched microdomains. Ann. N. Y. Acad. Sci. 845, 1–10 (1998)
Springer, G.F.: T and Tn, general carcinoma autoantigens. Science 224(4654), 1198–1206 (1984)
Maraveyas, A., Snook, D., Hird, V., Kosmas, C., Meares, C.F., Lambert, H.E., Epenetos, A.A.: Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 73(3 Suppl), 1067–1075 (1994)
DeNardo, S.J., Kramer, E.L., O’Donnell, R.T., Richman, C.M., Salako, Q.A., Shen, S., Noz, M., Glenn, S.D., Ceriani, R.L., DeNardo, G.L.: Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J. Nucl. Med. 38(8), 1180–1185 (1997)
Snijdewint, F.G., von Mensdorff-Pouilly, S., Karuntu-Wanamarta, A.H., Verstraeten, A.A., Livingston, P.O., Hilgers, J., Kenemans, P.: Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int. J. Cancer 93(1), 97–106 (2001)
Karanikas, V., Hwang, L.A., Pearson, J., Ong, C.S., Apostolopoulos, V., Vaughan, H., Xing, P.X., Jamieson, G., Pietersz, G., Tait, B., et al.: Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100(11), 2783–2792 (1997)
Apostolopoulos, V., Pietersz, G.A., Tsibanis, A., Tsikkinis, A., Drakaki, H., Loveland, B.E., Piddlesden, S.J., Plebanski, M., Pouniotis, D.S., Alexis, M.N., et al.: Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 8(3), R27 (2006)
Loveland, B.E., Zhao, A., White, S., Gan, H., Hamilton, K., Xing, P.X., Pietersz, G.A., Apostolopoulos, V., Vaughan, H., Karanikas, V., et al.: Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12(3 Pt 1), 869–877 (2006)
Goydos, J.S., Elder, E., Whiteside, T.L., Finn, O.J., Lotze, M.T.: A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63(1), 298–304 (1996)
Gilewski, T., Adluri, S., Ragupathi, G., Zhang, S., Yao, T.J., Panageas, K., Moynahan, M., Houghton, A., Norton, L., Livingston, P.O.: Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6(5), 1693–1701 (2000)
von Mensdorff-Pouilly, S., Petrakou, E., Kenemans, P., van Uffelen, K., Verstraeten, A.A., Snijdewint, F.G., van Kamp, G.J., Schol, D.J., Reis, C.A., Price, M.R., et al.: Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer 86(5), 702–712 (2000)
Finn, O.J., Jerome, K.R., Henderson, R.A., Pecher, G., Domenech, N., Magarian-Blander, J., Barratt-Boyes, S.M.: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61–89 (1995)
Wykes, M., MacDonald, K.P., Tran, M., Quin, R.J., Xing, P.X., Gendler, S.J., Hart, D.N., McGuckin, M.A.: MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J. Leukoc. Biol. 72(4), 692–701 (2002)
Brugger, W., Buhring, H.J., Grunebach, F., Vogel, W., Kaul, S., Muller, R., Brummendorf, T.H., Ziegler, B.L., Rappold, I., Brossart, P., et al.: Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J. Clin. Oncol. 17(5), 1535–1544 (1999)
Fattorossi, A., Battaglia, A., Malinconico, P., Stoler, A., Andreocci, L., Parente, D., Coscarella, A., Maggiano, N., Perillo, A., Pierelli, L., et al.: Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells. Exp. Cell Res. 280(1), 107–118 (2002)
Moreno, M., Bontkes, H.J., Scheper, R.J., Kenemans, P., Verheijen, R.H., von Mensdorff-Pouilly, S.: High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 257(1), 47–55 (2007)
Sabbatini, P.J., Ragupathi, G., Hood, C., Aghajanian, C.A., Juretzka, M., Iasonos, A., Hensley, M.L., Spassova, M.K., Ouerfelli, O., Spriggs, D.R., et al.: Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res. 13(14), 4170–4177 (2007)
Wandall, H.H., Blixt, O., Tarp, M.A., Pedersen, J.W., Bennett, E.P., Mandel, U., Ragupathi, G., Livingston, P.O., Hollingsworth, M.A., Taylor-Papadimitriou, J., et al.: Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 70(4), 1306–1313 (2010)
Pedersen, J.W., Blixt, O., Bennett, E.P., Tarp, M.A., Dar, I., Mandel, U., Poulsen, S.S., Pedersen, A.E., Rasmussen, S., Jess, P., et al.: Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 128(8), 1860–1871 (2011)
Tarp, M.A., Sorensen, A.L., Mandel, U., Paulsen, H., Burchell, J., Taylor-Papadimitriou, J., Clausen, H.: Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17(2), 197–209 (2007)
Kracun, S.K., Clo, E., Clausen, H., Levery, S.B., Jensen, K.J., Blixt, O.: Random glycopeptide bead libraries for seromic biomarker discovery. J. Proteome Res. 9(12), 6705–6714 (2010)
Wandall, H.H., Hassan, H., Mirgorodskaya, E., Kristensen, A.K., Roepstorff, P., Bennett, E.P., Nielsen, P.A., Hollingsworth, M.A., Burchell, J., Taylor-Papadimitriou, J., et al.: Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. J. Biol. Chem. 272(38), 23503–23514 (1997)
Bennett, E.P., Hassan, H., Clausen, H.: cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N-acetylgalactosaminyltransferase, GalNAc-t3. J. Biol. Chem. 271(29), 17006–17012 (1996)
White, T., Bennett, E.P., Takio, K., Sorensen, T., Bonding, N., Clausen, H.: Purification and cDNA cloning of a human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. J. Biol. Chem. 270(41), 24156–24165 (1995)
Ikehara, Y., Kojima, N., Kurosawa, N., Kudo, T., Kono, M., Nishihara, S., Issiki, S., Morozumi, K., Itzkowitz, S., Tsuda, T., et al.: Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. Glycobiology 9(11), 1213–1224 (1999)
Kurosawa, N., Takashima, S., Kono, M., Ikehara, Y., Inoue, M., Tachida, Y., Narimatsu, H., Tsuji, S.: Molecular cloning and genomic analysis of mouse GalNAc alpha2, 6-sialyltransferase (ST6GalNAc I). J. Biochem. 127(5), 845–854 (2000)
Burchell, J., Gendler, S., Taylor-Papadimitriou, J., Girling, A., Lewis, A., Millis, R., Lamport, D.: Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47(20), 5476–5482 (1987)
Beatson, R.E., Taylor-Papadimitriou, J., Burchell, J.M.: MUC1 immunotherapy. Immunotherapy 2(3), 305–327 (2010)
Burchell, J.M., Mungul, A., Taylor-Papadimitriou, J.: O-linked glycosylation in the mammary gland: changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia 6(3), 355–364 (2001)
Wang, B.L., Springer, G.F., Carlstedt, S.C.: Quantitative computerized image analysis of Tn and T (Thomsen-Friedenreich) epitopes in prognostication of human breast carcinoma. J. Histochem. Cytochem. 45(10), 1393–1400 (1997)
Van Elssen, C.H., Frings, P.W., Bot, F.J., Van de Vijver, K.K., Huls, M.B., Meek, B., Hupperets, P., Germeraad, W.T., Bos, G.M.: Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 57(4), 597–606 (2010)
Roda, J.M., Joshi, T., Butchar, J.P., McAlees, J.W., Lehman, A., Tridandapani, S., Carson 3rd, W.E.: The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin. Cancer Res. 13(21), 6419–6428 (2007)
Dunne, J., Lynch, S., O’Farrelly, C., Todryk, S., Hegarty, J.E., Feighery, C., Doherty, D.G.: Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J. Immunol. 167(6), 3129–3138 (2001)
Herberman, R.B., Ortaldo, J.R., Mantovani, A., Hobbs, D.S., Kung, H.F., Pestka, S.: Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell. Immunol. 67(1), 160–167 (1982)
Roda, J.M., Parihar, R., Lehman, A., Mani, A., Tridandapani, S., Carson 3rd, W.E.: Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 177(1), 120–129 (2006)
Ragupathi, G., Liu, N.X., Musselli, C., Powell, S., Lloyd, K., Livingston, P.O.: Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol. 174(9), 5706–5712 (2005)
Juhl, H., Helmig, F., Baltzer, K., Kalthoff, H., Henne-Bruns, D., Kremer, B.: Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J. Surg. Oncol. 64(3), 222–230 (1997)
Yu, J., Caragine, T., Chen, S., Morgan, B.P., Frey, A.B., Tomlinson, S.: Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin. Exp. Immunol. 115(1), 13–18 (1999)
Geis, N., Zell, S., Rutz, R., Li, W., Giese, T., Mamidi, S., Schultz, S., Kirschfink, M.: Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr. Cancer Drug Targets 10(8), 922–931 (2010)
Price, M.R., Rye, P.D., Petrakou, E., Murray, A., Brady, K., Imai, S., Haga, S., Kiyozuka, Y., Schol, D., Meulenbroek, M.F., et al.: Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol. 19(Suppl 1), 1–20 (1998)
Courtenay-Luck, N., Pegram, M.: Phase I study of the anti-MUC-1 antibody, huHMFG1 (AS1402), in patients with advanced breast cancer. Clin. Immunol. 123, S110–S111 (2007)
Wahrenbrock, M.G., Varki, A.: Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the “tip of the iceberg”? Cancer Res. 66(4), 2433–2441 (2006)
Fan, X.N., Karsten, U., Goletz, S., Cao, Y.: Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol. Res. Pract. 206(8), 585–589 (2010)
Danielczyk, A., Stahn, R., Faulstich, D., Loffler, A., Marten, A., Karsten, U., Goletz, S.: PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol. Immunother. 55(11), 1337–1347 (2006)
Parham, P.: The genetic and evolutionary balances in human NK cell receptor diversity. Semin. Immunol. 20(6), 311–316 (2008)
Ferris, R.L., Jaffee, E.M., Ferrone, S.: Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28(28), 4390–4399 (2010)
Acknowledgments
We would like to express our gratitude for the exceptional laboratory support provided by Karin U. Hansen. We thank Joyce Taylor-Papadimitriou and Joy Burchell for the generous gift of mAb HMFG2. This project was supported by the Novo Nordisk Foundation, the Danish Medical Research Council, the Danish Cancer Research Foundation, the Agnes and Poul Friis Foundation, the Danish Cancer Society, the University of Copenhagen (Program of Excellence), EU-FP7, Danish Agency for Science, Technology and Innovation (FTP).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lavrsen, K., Madsen, C.B., Rasch, M.G. et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J 30, 227–236 (2013). https://doi.org/10.1007/s10719-012-9437-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10719-012-9437-7